Rachid Rafia

All publications

Journal articles

• Harnan S, Tappenden P, Cooper K, Stevens J, Bessey A, Rafia R, Ward S, Wong R, Stein RC & Brown J (2019) Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer: a systematic review and economic analysis. Health Technology Assessment, 23(30). View this article in WRRO
• Davis S, Rafia R, Carroll C, Hamilton J & Essat M (2018) Pirfenidone for Treating Idiopathic Pulmonary Fibrosis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.. Pharmacoeconomics. View this article in WRRO
• Rafia R, Pandor A, Davis S, Stevens JW, Harnan S, Clowes M, Sorour Y & Cutting R (2018) Obinutuzumab with Bendamustine for Treating Follicular Lymphoma Refractory to Rituximab: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics, 36(10), 1143-1151. View this article in WRRO
• Scope A, Essat M, Pandor A, Rafia R, Ward S, Wyld L, Cross S & Woods H (2017) Gene expression profiling and expanded immunohistochemistry tests to guide selection of chemotherapy regimens in breast cancer management: a systematic review.. International Journal of Technology Assessment in Health Care, 33(1), 32-45. View this article in WRRO
• Carroll C, Tappenden P, Rafia R, Hamilton J, Chambers D, Clowes M, Durrington P, Qureshi N & Wierzbicki AS (2017) Evolocumab for Treating Primary Hypercholesterolaemia and Mixed Dyslipidaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics, 35(5), 537-547. View this article in WRRO
• Kearns B, Rafia R, Leaviss J, Preston L, Brazier JE, Palmer S & Ara R (2017) The cost-effectiveness of changes to the care pathway used to identify depression and provide treatment amongst people with diabetes in England: a model-based economic evaluation. BMC Health Services Research, 17(1), 78-78. View this article in WRRO
• Rafia R, Dodd PJ, Brennan A, Meier PS, Hope VD, Ncube F, Byford S, Tie H, Metrebian N, Hellier J , Weaver T et al (2016) An economic evaluation of contingency management for completion of hepatitis B vaccination in those on treatment for opiate dependence. Addiction, 111(9), 1616-1627. View this article in WRRO
• Rafia R, Scope A, Harnan S, Stevens JW, Stevenson M & Lobo A (2016) Vedolizumab for Treating Moderately to Severely Active Crohn’s Disease After Prior Therapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics, 34(12), 1241-1253. View this article in WRRO
• Stevenson M, Pandor A, Martyn-St James M, Rafia R, Uttley L, Stevens J, Sanderson J, Wong R, Perkins GD, McMullan R & Dark P (2016) Sepsis: the LightCycler SeptiFast Test MGRADE®, SepsiTest™ and IRIDICA BAC BSI assay for rapidly identifying bloodstream bacteria and fungi - a systematic review and economic evaluation.. Health Technology Assessment, 20(46), 1-246. View this article in WRRO
• Rafia R, Brennan A, Madan J, Collins K, Reed MWR, Lawrence G, Robinson T, Greenberg D & Wyld L (2016) Modeling the Cost-Effectiveness of Alternative Upper Age Limits for Breast Cancer Screening in England and Wales. Value in Health, 19(4), 404-412.
• Carroll C, Tappenden P, Rafia R, Hamilton J, Chambers D, Clowes M, Durrington P, Qureshi N & Wierzbicki AS (2016) Evolocumab for Treating Primary Hypercholesterolaemia and Mixed Dyslipidaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics, 35(5), 537-547.
• Brennan A, Meier P, Purshouse R, Rafia R, Meng Y & Hill-Macmanus D (2016) Developing policy analytics for public health strategy and decisions—the Sheffield alcohol policy model framework. Annals of Operations Research, 236(1), 149-176. View this article in WRRO
• Brennan A, Meier P, Purshouse R, Rafia R, Meng Y, Hill-Macmanus D, Angus C & Holmes J (2015) The Sheffield Alcohol Policy Model - A Mathematical Description. Health Economics, 24(10), 1368-1388. View this article in WRRO
• Ward S, Scope A, Rafia R, Pandor A, Harnan S, Evans P & Wyld L (2013) Gene expression profiling and expanded immunohistochemistry tests to guide the use of adjuvant chemotherapy in breast cancer management: a systematic review and cost-effectiveness analysis.. Health Technol Assess, 17(44), 1-302. View this article in WRRO
• Rafia R, Simpson E, Stevenson M & Papaioannou D (2013) Trabectedin for the treatment of advanced metastatic soft tissue sarcoma: a NICE single technology appraisal.. Pharmacoeconomics, 31(6), 471-478.
• Purshouse RC, Brennan A, Rafia R, Latimer NR, Archer RJ, Angus CR, Preston LR & Meier PS (2013) Modelling the cost-effectiveness of alcohol screening and brief interventions in primary care in England.. Alcohol Alcohol, 48(2), 180-188.
• Papaioannou D, Rafia R, Rathbone J, Stevenson M, Buckley Woods H & Stevens J (2012) Rituximab for the first-line treatment of stage III-IV follicular lymphoma (review of Technology Appraisal No. 110): a systematic review and economic evaluation.. Health Technol Assess, 16(37), 1-iv.
• Rafia R, Ara R, Packham J, Haywood KL & Healey E (2012) Healthcare costs and productivity losses directly attributable to ankylosing spondylitis.. Clin Exp Rheumatol, 30(2), 246-253.
• Ara R, Pandor A, Stevens J, Rafia R, Ward SE, Rees A, Durrington PN, Reynolds TM, Wierzbicki AS & Stevenson M (2012) Prescribing high-dose lipid-lowering therapy early to avoid subsequent cardiovascular events: is this a cost-effective strategy?. Eur J Prev Cardiol, 19(3), 474-483.
• Papaioannou D, Rafia R, Stevenson MD, Stevens JW & Evans P (2011) Trabectedin for the treatment of relapsed ovarian cancer.. Health Technol Assess, 15 Suppl 1, 69-75.
• Poole CD, Lebmeier M, Ara R, Rafia R & Currie CJ (2010) Estimation of health care costs as a function of disease severity in people with psoriatic arthritis in the UK.. Rheumatology (Oxford), 49(10), 1949-1956.
• Simpson EL, Rafia R, Stevenson MD & Papaioannou D (2010) Trabectedin for the treatment of advanced metastatic soft tissue sarcoma.. Health Technol Assess, 14 Suppl 1, 63-67.
• Purshouse RC, Meier PS, Brennan A, Taylor KB & Rafia R (2010) Estimated effect of alcohol pricing policies on health and health economic outcomes in England: an epidemiological model.. Lancet, 375(9723), 1355-1364.
• Tappenden P, Saccardi R, Confavreux C, Sharrack B, Muraro PA, Mancardi GL, Kozak T, Farge-Bancel D, Madan J, Rafia R , Akehurst R et al (2010) Autologous haematopoietic stem cell transplantation for secondary progressive multiple sclerosis: an exploratory cost-effectiveness analysis.. Bone Marrow Transplant, 45(6), 1014-1021.
• Ara R, Rafia R, Ward SE, Wierzbicki AS, Reynolds TM, Rees A & Pandor A (2009) Are intensive lipid-lowering regimens an optimal economic strategy in patients with ACS? An acute and chronic perspective.. Expert Rev Pharmacoecon Outcomes Res, 9(5), 423-433.
• Ara R, Pandor A, Stevens J, Rees A & Rafia R (2009) Early high-dose lipid-lowering therapy to avoid cardiac events: a systematic review and economic evaluation.. Health technology assessment (Winchester, England), 13(34).
• Szucs TD, Largeron N, Dedes KJ, Rafia R & Bénard S (2008) Cost-effectiveness analysis of adding a quadrivalent HPV vaccine to the cervical cancer screening programme in Switzerland.. Curr Med Res Opin, 24(5), 1473-1483.
• Dhont P, Trichard M, Largeron N, Rafia R & Bénard S (2008) Burden of rotavirus gastroenteritis and potential benefits of a pentavalent rotavirus vaccination in Belgium.. J Med Econ, 11(3), 431-448.

Conference proceedings papers

• Rafia R & Mukuria CW (2015) Exploratory Psychometric Analysis of The Eq-5d In A Myelofibrosis Population. Value in Health, Vol. 18(3) (pp A211-A211)
• Mukuria CW, Brazier J & Rafia R (2015) Does the generic cancer outcome measure eortc qlq-c30 work in myelofibrosis?. Value in Health, Vol. 18(3) (pp A210-A211)
• Rafia R & Ward SE (2014) Approaches Used to Model the Relationship Between Progression-Free Survival (PFS) / Time-To-Progression (TTP) And Overall Survival (OS) Within Health Economic Models of Cancer Therapies. Value in Health, Vol. 17(7) (pp A557-A557)
• Rafia R, Ward SE, Scope A & Wyld L (2013) EVALUATING THE COST EFFECTIVENESS OF GENE EXPRESSION PROFILING AND IMMUNOHISTOCHEMISTRY TESTS. VALUE IN HEALTH, Vol. 16(7) (pp A413-A413)
• Rafia R, Papaioannou D, Stevenson M, Rathbone J & Woods HB (2011) EVALUATING THE COST-EFFECTIVENESS OF THE ADDITION OF RITUXIMAB TO CHEMOTHERAPY IN THE FIRST LINE TREATMENT OF FOLLICULAR LYMPHOMA PATIENTS IN THE UK. VALUE IN HEALTH, Vol. 14(7) (pp A445-A445)
• Ara R, Rafia R, Packham J, Haywood K & Healey E (2010) HEALTHCARE COSTS ALONE DO NOT DESCRIBE THE TOTAL COSTS DIRECTLY ATTRIBUTABLE TO ANKYLOSING SPONDYLITIS. RHEUMATOLOGY, Vol. 49 (pp I70-I70)
• Rafia R, Ara R & Lebmeier M (2010) THE COST EFFECTIVENESS OF ETANERCEPT IN PATIENTS WITH PSORIATIC ARTHRITIS IN THE UK. RHEUMATOLOGY, Vol. 49 (pp I75-I75)

Reports

• Kearns B, Rafia R, Leaviss J, Preston L, Wong R, Brazier J, Palmer S & Ara R (2014) Whole pathway modelling of depression in patients. (Theme 2: Mental Health). Appendices.
• Kearns B, Rafia R, Leaviss J, Preston L, Wong R, Brazier J, Palmer S & Ara R (2014) Whole pathway modelling of depression in patients. (Theme 2: Mental Health). Part 1, Executive summary, introduction, clinical reviews and conceptual modelling.
• Kearns B, Rafia R, Leaviss J, Preston L, Wong R, Brazier J, Palmer S & Ara R (2014) Whole pathway modelling of depression in patients. (Theme 2: Mental Health). Part 2. Independent economic evaluation: methods and results, discussion and conclusion

Posters

• Rafia R & Mukuria C Exploratory psychometric analysis of the EQ-5D in a Myelofibrosis population (ISPOR 20th Annual International Meeting 16-20 May 2015).
• Mukuria C, Brazier J & Rafia R Does the generic cancer outcome measure EORTC QLQ-C30 work in Myelofibrosis? (ISPOR 20th Annual International Meeting 16-20 May 2015).
• Rafia R, Papaioannou D, Stevenson M, Rathbone J & Woods H Evaluating the cost-effectiveness of the addition of rituximab to chemotherapy in the first-line treatment of Follicular Lymphoma patients in the UK.